Publikationen (28) Publikationen, an denen Forscher/innen teilgenommen haben

2024

  1. Chronic sarpogrelate treatment improves renal sympathetic hyperactivity in experimental diabetes

    Biomedicine and Pharmacotherapy, Vol. 176

  2. Sex influence on serotonergic modulation of the vascular noradrenergic drive in rats

    British Journal of Pharmacology

2023

  1. Bispecific sigma-1 receptor antagonism and mu-opioid receptor partial agonism: WLB-73502, an analgesic with improved efficacy and safety profile compared to strong opioids

    Acta Pharmaceutica Sinica B, Vol. 13, Núm. 1, pp. 82-99

  2. Cohort Profile: PISCIS, a population-based cohort of people living with HIV in Catalonia and Balearic Islands

    International Journal of Epidemiology, Vol. 52, Núm. 4, pp. E241-E252

  3. Fármacos que actúan modulando la actividad enzimática

    Fundamentos de farmacología básica y clínica (Editorial Médica Panamericana), pp. 101-112

  4. Renal Sympathetic Hyperactivity in Diabetes Is Modulated by 5-HT1D Receptor Activation via NO Pathway

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

2022

  1. Effect of sarpogrelate treatment on 5-HT modulation of vascular sympathetic innervation and platelet activity in diabetic rats

    Biomedicine and Pharmacotherapy, Vol. 153

  2. Fluoxetine Treatment Decreases Cardiac Vagal Input and Alters the Serotonergic Modulation of the Parasympathetic Outflow in Diabetic Rats

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

  3. Oral fluoxetine treatment changes serotonergic sympatho-regulation in experimental type 1 diabetes

    Life Sciences, Vol. 293

2021

  1. Piperazinyl Bicyclic Derivatives as Selective Ligands of the α2δ-1 Subunit of Voltage-Gated Calcium Channels

    ACS Medicinal Chemistry Letters, Vol. 12, Núm. 11, pp. 1802-1809

  2. Propionamide Derivatives as Dual μ-Opioid Receptor Agonists and σ1Receptor Antagonists for the Treatment of Pain

    Journal of Medicinal Chemistry, Vol. 64, Núm. 14, pp. 10139-10154

  3. Trends in the use of anxiolytics in castile and leon, spain, between 2015–2020: Evaluating the impact of covid-19

    International Journal of Environmental Research and Public Health, Vol. 18, Núm. 11

  4. Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment

    Journal of Pharmacological Sciences, Vol. 147, Núm. 1, pp. 48-57

2020

  1. 4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ1 Receptor Antagonists for the Treatment of Pain

    Journal of Medicinal Chemistry, Vol. 63, Núm. 5, pp. 2434-2454

  2. Blockade of 5-HT2 receptors with sarpogrelate uncovers 5-HT7 receptors inhibiting the tachycardic sympathetic drive in pithed rats

    Clinical and Experimental Pharmacology and Physiology, Vol. 47, Núm. 3, pp. 403-411

  3. Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ1Receptor Antagonist Clinical Candidate for the Treatment of Pain

    Journal of Medicinal Chemistry, Vol. 63, Núm. 24, pp. 15508-15526

  4. Dopamine D4 receptor subtype activation reduces the rat cardiac parasympathetic discharge

    Pflugers Archiv European Journal of Physiology, Vol. 472, Núm. 12, pp. 1693-1703

  5. EST64454: A Highly Soluble σ1Receptor Antagonist Clinical Candidate for Pain Management

    Journal of Medicinal Chemistry, Vol. 63, Núm. 23, pp. 14979-14988

  6. Role of peripheral 5-HT5A receptors in 5-HT-induced cardiac sympatho-inhibition in type 1 diabetic rats

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Fluoxetine oral treatment discloses 5-HT 1D receptor as vagoinhibitor of the cardiac cholinergic neurotransmission in rat

    Canadian Journal of Physiology and Pharmacology, Vol. 97, Núm. 2, pp. 90-98